Navigation Links
Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
Date:4/9/2008

ion Center

Preclinical data providing new details on SNS-314's anti-tumor activity will be presented Wednesday, April 16, 2008. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors.

SNS-314 Poster Presentation

Wednesday, April 16, 2008

-- SNS-314, a potent inhibitor of Aurora kinases, has preclinical

anti-activity and induces apoptosis

Session: Heat Shock Protein Inhibitors, Aurora Kinase and other Mitotic

Inhibitors

Abstract #5648

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
2. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
9. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 The Physician-Patient Alliance ... on July 28, 2015, "Surviving Your Hospital Stay: ... for Patient Safety." A sentence was ... read: "PPAHS is a member of ... Opioids. For more information on the National Coalition to ...
(Date:7/31/2015)...  Xcelience, a contract development and manufacturing organization ... structured cash investment in Powdersize, a ... and powder size classification within the pharmaceutical industry.  ... simultaneously adding a complete set of particle size ... "As we continue to build our ...
(Date:7/31/2015)... PORTLAND, Ore., July 31, 2015  Semler Scientific, Inc. ... and testing services to healthcare insurers and physician groups, ... June 30, 2015. "In the second ... over year revenue growth of 54%, quarter over quarter ... of the installed base of FloChec® units of 18%," ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... SAN DIEGO, Jan. 19, 2012 Sequenom, Inc. (NASDAQ: SQNM ... to market and other conditions, shares of its common stock in ... whether or when the offering may be completed, or as to ... & Company, Inc. is acting as sole book-running manager for the ...
... 19, 2012 Medicare officials should swiftly authorize a Special ... Medicare Part D prescription drug plan if the patient believes ... "preferred network" plan with inadequate pharmacy access, the National ... the start of the 2012 plan year on January 1, ...
Cached Medicine Technology:Sequenom Announces Proposed Public Offering of Common Stock 2Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 2Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 3
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director ... August. The new facility is licensed under Dignity Health Arizona General Hospital ... is an excellent leader and will ensure our new freestanding emergency room delivers the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Hub International Insurance ... Williams has joined its growing California employee benefits division. Mr. Williams will ... his clients. Mr. Williams will be joining the newly integrated Northern California employee ...
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from ... tissue injury caused by diabetes after many years of suffering and using medications with ... he didn’t want to ask for extra time off or wait longer hours in ...
(Date:8/3/2015)... ... August 03, 2015 , ... Cambia Health Solutions has promoted ... the company’s Medicare and Federal Employee Programs (FEP) lines of business. , ... for members. In this role, Scott is responsible for overseeing the growth, finance ...
(Date:8/3/2015)... ... 03, 2015 , ... Foot and Ankle Specialists of the Mid-Atlantic (FASMA) ... largest medical practice in the Mid-Atlantic region – and the second largest in the ... 33 doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland native. She grew up in ...
Breaking Medicine News(10 mins):Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4
... specialists from all over the world will meet at Mount ... heart disease in India and how preventive measures can help ... on Clinical & Preventive Cardiology is being held from September ... for several burning issues and newer technologies besides crystallizing recent ...
... recent clinical trials of inhaled insulin has received the approval ... in regulating blood sugar levels spanning a 2 year period. ... introduced into the United States market soon after the U.S. ... with Type 1 or Type 2 diabetes. ,Dr. Julio ...
... said that the breast cancer drug Herceptin was approved to be ... happy news to the grieving family of Tamar Bailey. //She is ... denied her the drug which led to her early death. She ... was an advertising art director from Wimbledon, south-west London. She had ...
... National Institute of Standards and Technology (NIST) researchers have ... of complex surfaces, which vary in a controlled fashion ... is so flexible that it can be applied to ... exploring the bonding of proteins to cell membranes. ...
... first spacewalk was successfully by two crewmen in the early ... jobs on the international space station within 6.5 hours on ... 8 hours and 56 minutes. Except for a video camera ... placed on a transport platform. ,After Russians have ...
... - high school and college students are now co-authors in ... of 30 macrophages has been made possible by digging in ... 9, 2006 has a report of a research team lead ... The report is about the characterization and cataloguing of genomes ...
Cached Medicine News:Health News:World Cong On Preventive Cardiology In Sept 2Health News:New Technique For Science Experiments 2
... Room Knee Brace frees the ... the time-consuming post-op fitting and ... more complex brace designs. The ... provides the same benefits as ...
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
Medicine Products: